Phaseline

Companies › Valo Therapeutics Oy

Valo Therapeutics Oy: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PeptiCRAd-1
Peptide-coated conditionally replicating adenovirus
–Phase 1Melanoma (Skin)Apr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05492682PeptiCRAd-1Phase 1Melanoma (Skin)OncologyApr 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.